Stockreport

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern Pharma Inc.  (LTRN) 
PDF Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical [Read more]